Please login to the form below
RLF-100
This page shows the latest RLF-100 news and features for those working in and with pharma, biotech and healthcare.
Relief Therapeutics’ COVID-19 drug shows positive results ahead of trial readout
Relief and NeuroRx are still awaiting the detailed results from rigorous randomised studies of RLF-100 (aviptadil) for the treatment of COVID-19 patients. ... The companies said that 81% of patients treated with RLF-100 survived beyond 60 days, compared
Latest news
-
Relief Therapeutics seeks US emergency approval for COVID-19 drug
The companies are requesting an approval for RLF-100 (aviptadil) as a treatment for COVID-19 patients who are receiving intensive care and who have exhausted all approved treatments. ... According to Relief Therapeutics, patients treated with RLF-100
-
NeuroRx, Relief Therapeutics’ COVID-19 drug demonstrates early potential
patients. Currently, RLF-100 (aviptadil) is being tested in an ongoing phase 2/3 trial and is also being administered to patients on an emergency use basis. ... After treatment with RLF-100, the patient was able to come off a ventilator within four days.
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- NHS App to revolutionise digital health and care with major digital updates by 2023
- A new era for UK-Japanese scientific research relations
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
PMHub
Empowering Strategic Performance Ltd
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
